1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps
Key Takeaways
- The Mosteller formula, BSA in square meters equals the square root of height in centimeters times weight in kilograms divided by 3,600, is the standard body surface area calculation for pediatric chemotherapy because it is reproducible at the bedside and requires only two measurements.
- Body surface area dosing is generally avoided in infants under 12 months or under 10 kg; oncology protocols convert to weight-based dosing by dividing the square-meter dose by 30, so a 1,200 mg/m2 dose becomes 40 mg/kg.
- Ideal body weight in children aged 2 to 20 years is most defensibly calculated as the 50th percentile BMI-for-age multiplied by height in meters squared, and adjusted body weight equals ideal body weight plus 0.4 times the difference between total and ideal body weight.
- In pediatric obesity, total body weight is used for vancomycin, cefazolin, most beta-lactams, succinylcholine, and enoxaparin; adjusted body weight with a 0.4 factor is used for aminoglycosides; and ideal or adjusted body weight is used for acyclovir, with therapeutic drug monitoring wherever available.
- A weight-based pediatric dose must never exceed the maximum recommended adult dose, so every calculation in a child above roughly 40 kg requires an explicit cap check before verification.
1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps
Pediatric dosing is an act of scaling. The question is never simply "how much drug?" but "how much drug per unit of what?" — per kilogram of total body weight, per kilogram of some adjusted weight, or per square meter of body surface area. Choosing the wrong size descriptor produces a dose that is numerically defensible and clinically wrong, and this failure mode is heavily represented on the BCPPS examination because it is heavily represented in real pediatric harm.
Three measurements are non-negotiable before verifying any pediatric order: a weight recorded in kilograms only, a recent weight (a dosing weight more than a few days old is invalid in a neonate and unreliable in a fluid-overloaded critically ill child), and a length or height whenever body surface area is involved.
Body Surface Area
BSA correlates better than weight with basal metabolic rate, cardiac output, glomerular filtration rate, and extracellular fluid volume — the physiologic quantities that govern the clearance of cytotoxic agents. That is why oncology, and a handful of other domains such as some immunosuppressants and antifungals, dose by square meter.
The Three Formulas
| Formula | Equation | Where used |
|---|---|---|
| Mosteller (standard) | $\text{BSA (m}^2) = \sqrt{\dfrac{\text{Height (cm)} \times \text{Weight (kg)}}{3600}}$ | The default in pediatric oncology; simple enough to reproduce at the bedside and to double-check independently |
| DuBois & DuBois | $\text{BSA} = 0.007184 \times \text{Ht(cm)}^{0.725} \times \text{Wt(kg)}^{0.425}$ | Historical standard; derived in only nine subjects, one of them a child |
| Haycock | $\text{BSA} = 0.024265 \times \text{Ht(cm)}^{0.3964} \times \text{Wt(kg)}^{0.5378}$ | Derived specifically in infants and children; sometimes preferred in neonatology |
The formulas agree closely in school-age children and diverge most in neonates and in severe obesity. Do not mix formulas within a treatment course — the protocol that defined the dose also defined the formula.
Worked Calculation
A 7-year-old is 120 cm tall and weighs 25 kg. Vincristine is ordered at 1.5 mg/m².
The conventional 2 mg absolute cap on a single vincristine dose is not exceeded, so 1.4 mg is dispensed. Had the child been 160 cm and 60 kg, BSA would be 1.63 m² and the uncapped calculation 2.45 mg — which must be capped at 2 mg.
The Infant Exception and the "Rule of 30"
Body surface area rises disproportionately to weight in small infants, so square-meter dosing systematically overdoses them. Pediatric oncology protocols therefore convert to weight-based dosing for patients who are under 12 months of age or under 10 kg (some protocols use under 12 kg):
Cyclophosphamide 1,200 mg/m² becomes 40 mg/kg. Applying the m² dose directly to a 5 kg infant would deliver roughly a 50% overdose of a drug with a narrow therapeutic index.
[!WARNING] Vincristine is the paradigm high-alert pediatric oncology drug: fatal if administered intrathecally. Independent of any BSA arithmetic, vincristine must be dispensed in a minibag, never a syringe, and labeled "For intravenous use only — fatal if given by other routes."
Selecting the Dosing Weight
CHOOSING A SIZE DESCRIPTOR
Is the patient a neonate (<= 28 days)?
|-- YES -> Use BIRTH WEIGHT for the first 7-14 days of life,
| then current weight once birth weight is regained.
| Never dose on a weight inflated by edema.
|
|-- NO -> Is BMI-for-age >= 95th percentile (obesity)?
|-- NO -> TOTAL BODY WEIGHT, with an adult max cap.
|
|-- YES -> Drug-specific descriptor (see table below),
with an adult max cap and TDM if available.
Calculating Ideal and Adjusted Body Weight in Children
Adult equations such as Devine (50 kg + 2.3 kg per inch over 5 feet for males) are invalid below about 5 feet in height and therefore unusable in most children. The defensible pediatric method uses the growth chart itself:
Worked example. A 10-year-old boy is 1.40 m tall and weighs 60 kg. The 50th percentile BMI-for-age at 10 years is approximately 16.5 kg/m².
- $\text{IBW} = 16.5 \times (1.40)^2 = 16.5 \times 1.96 = 32.3\ \text{kg}$
- $\text{AdjBW} = 32.3 + 0.4(60 - 32.3) = 32.3 + 11.1 = 43.4\ \text{kg}$
- Gentamicin at 7 mg/kg extended interval: $7 \times 43.4 = 304\ \text{mg}$, not $7 \times 60 = 420\ \text{mg}$.
Dosing that child's aminoglycoside on total body weight would deliver a 38% excess, because adipose tissue contributes almost nothing to the volume of distribution of a hydrophilic aminoglycoside.
Size Descriptor by Drug Class in Pediatric Obesity
| Drug or class | Descriptor | Rationale and caveat |
|---|---|---|
| Vancomycin | Total body weight | Clearance scales with total body weight; obese children generally need fewer mg/kg. Dose to an AUC24/MIC of 400–600 and cap the total daily dose (commonly 4,500 mg/day with a 2 g single-dose cap at many centers). |
| Aminoglycosides | Adjusted body weight, factor 0.4 | Hydrophilic; adipose contributes minimally to $V_d$. Mandatory therapeutic drug monitoring. |
| Acyclovir (IV) | Ideal or adjusted body weight | Total body weight dosing produces excessive exposure and crystalline nephropathy; hydrate aggressively and monitor renal function. |
| Cefazolin, most beta-lactams | Total body weight, capped at the adult maximum | Time-dependent killing; underdosing risks failure more than overdosing risks toxicity. |
| Enoxaparin | Total body weight | Monitor anti-Xa; obese children often need less per kilogram than lean children. |
| Unfractionated heparin, warfarin | Total body weight with early monitoring | Obese children frequently require fewer units or milligrams per kilogram. |
| Succinylcholine | Total body weight | Extracellular-fluid distribution and plasma cholinesterase activity both track total body weight. |
| Antineoplastics | Total body weight or full uncapped BSA | Reducing chemotherapy doses in obese patients is associated with worse outcomes; do not cap BSA at 2.0 m² unless the protocol says so. |
| Propofol | Lean body weight for induction, total body weight for maintenance infusion | Beware propofol infusion syndrome with prolonged high-rate infusion in children. |
| Digoxin | Ideal body weight | Distributes to lean tissue and skeletal muscle, not fat. |
The Maximum-Dose Cap Belongs to the Size Calculation
Weight-based arithmetic has no upper bound; children do. Once a child approaches adult size, the weight-based dose must be compared against the adult maximum and the lower value dispensed:
Drug-by-drug caps and the clinical consequences of exceeding them are tabulated in the high-alert medication section of the medication safety chapter. What belongs here is the ordering of operations: choose the size descriptor first, calculate second, cap third. Selecting the right descriptor does not exempt the result from the cap, and applying the cap does not excuse having used the wrong descriptor. An obese adolescent dosed on total body weight for an aminoglycoside and then capped at an adult maximum is still being dosed on the wrong denominator.
[!IMPORTANT] The reverse error also exists. An adolescent weighing 80 kg who is prescribed an adult fixed dose of a drug that is normally weight-based — for instance a 1 g vancomycin dose rather than 15–20 mg/kg — may be substantially underdosed. The cap rule is a ceiling, not a substitute for the calculation.
Practice Pearls & BCPPS Exam Traps
- Exam Trap 1: Height, not just weight, is required for BSA. An order for a square-meter dose without a documented current height cannot be verified; a stated BSA carried forward from a prior admission is a common source of silent chemotherapy error.
- Exam Trap 2: "Rounding" a BSA-derived chemotherapy dose to a convenient vial size is prohibited unless the protocol specifies a rounding tolerance (typically within 5%).
- Exam Trap 3: Do not use adult Devine or Robinson ideal-body-weight equations in a child under 152 cm; they return nonsensical or negative values. Use the 50th percentile BMI-for-age method.
- Board Rule: Any pediatric order that generates a dose at or above the adult maximum must stop at the adult maximum and prompt a call to the prescriber — with the single documented exception of antineoplastic protocols that explicitly direct full uncapped BSA dosing in obesity.
A 5-month-old infant weighing 6.2 kg with stage 4 neuroblastoma is prescribed cyclophosphamide. The treatment protocol specifies 1,200 mg/m2 per dose for patients 12 months of age and older and directs conversion to weight-based dosing for infants. The infant's calculated body surface area is 0.32 m2. Which dose should the pediatric clinical pharmacist verify?
A 12-year-old girl is 1.50 m tall and weighs 78 kg, placing her BMI well above the 95th percentile for age. She requires extended-interval tobramycin at 7 mg/kg for a cystic fibrosis pulmonary exacerbation. The 50th percentile BMI-for-age at her age and sex is approximately 18.5 kg/m2. Which dosing weight and dose should the pharmacist recommend?
A pediatric clinical pharmacist verifies an order for a 14-year-old weighing 85 kg: ondansetron 0.15 mg/kg IV every 8 hours for chemotherapy-induced nausea. Which action is correct?